Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has dosed the first patient with its TT-301 drug candidate in a Phase 1 clinical study. TT-301 has demonstrated efficacy in preclinical models of rheumatoid arthritis, intra cerebral haemorrhage (ICH) and traumatic brain injury (TBI).
The Company said data from the trial are a first step in the development of TT-301 for central nervous system intravenous indications, ICH and TBI. In follow up studies, Transition plans to advance oral formulations of lead drug candidates TT-301 or TT-302 for inflammatory diseases such as rheumatoid arthritis.
Both compounds can suppress inflammatory cytokine production, reduce inflammation and improve outcomes in preclinical models of collagen-induced arthritis. Currently, Phase 1 enabling preclinical studies are being performed for oral forms of both compounds.
